Sign In
Buy DYAI
$0.701
+0.0113 (+1.64%)
At Close: Jun 03, 2026
DYAI's C1 Technology May be Key in the Race to Vaccine-Induced Herd Immunity
07:44am, Wednesday, 12'th May 2021
Dyadic International Inc (NASDAQ: DYAI) is in an interesting position, being one of the very few names in the anti-Covid space that offer a new path that isn't simply a reproduction or tie-in to the b
Dyadic to Report First Quarter 2021 Financial Results
04:00pm, Thursday, 29'th Apr 2021
JUPITER, FL / ACCESSWIRE / April 29, 2021 / Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a global biotechnology company focused on further improving, apply
Fireside Chat Being Held on Tuesday, May 4th @ 10am Eastern Time Fireside Chat Being Held on Tuesday, May 4th @ 10am Eastern Time
Bloomberg reported this morning that the world's wealthiest countries are vaccinating 25 times faster than the poorest. As of April 8, 40% of the shots administered have gone to people in 27 nations t
Dyadic International Inc's (DYAI) CEO Mark Emalfarb on Q4 2020 Results - Earnings Call Transcript
12:28am, Wednesday, 31'st Mar 2021
Dyadic International Inc's (DYAI) CEO Mark Emalfarb on Q4 2020 Results - Earnings Call Transcript
Dyadic Reports 2020 Year End Results and Recent Company Progress
04:00pm, Tuesday, 30'th Mar 2021
Advancing Dyadic ' s proprietary COVID-19 vaccine candidate, DYAI-100, towards a first-in-human Phase 1 clinical trial To validate C1 produced proteins are safe in humans and accelerate C1 adoption an
Dyadic and Medytox To Develop Vaccines Against COVID-19 Variants
09:00pm, Monday, 22'nd Mar 2021
JUPITER, Fla., March 22, 2021 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused
DYAI Stock: Why Covid-19 Vaccine Play Dyadic Is Shooting Higher Today
04:03pm, Monday, 22'nd Mar 2021
Dyadic International is surging today after it announced a Covid vaccine partnership with Medytox, but that isn't the only bullish news for this small cap biotech stock. The post DYAI Stock: Why Covid
Why Odonate, Marker Therapeutics and Dyadic Are Moving Monday
10:16am, Monday, 22'nd Mar 2021
Odonate Therapeutics, Inc. (NASDAQ: ODT), Dyadic International, Inc. (NASDAQ: DYAI) and Marker Therapeutics, Inc. (NASDAQ: MRKR) are among the early biotech movers in Monday's session. Odonate to Shut
Dyadic to Report Fourth Quarter and Full Year 2020 Financial Results
04:00pm, Tuesday, 16'th Mar 2021
JUPITER, FL / ACCESSWIRE / March 16, 2021 / Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a global biotechnology company focused on further improving, apply
Dyadic Announces Scientific Achievements Reported During ZAPI Stakeholders Virtual Web Meeting
08:30am, Tuesday, 09'th Mar 2021
Results demonstrate that Dyadic's C1 platform produced record levels of safe and effective vaccines in animal trials and further positions C1 products for potential human clinical trials Results demon
Dyadic International Appoints New Board Member
08:30am, Monday, 11'th Jan 2021
JUPITER, FL / ACCESSWIRE / January 11, 2021 / Dyadic International, Inc. ("Dyadic") (NASDAQ:DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene exp
Nuveen Asset Management LLC Invests $788,000 in Dyadic International, Inc (NASDAQ:DYAI)
04:38am, Sunday, 18'th Oct 2020
Nuveen Asset Management LLC acquired a new position in shares of Dyadic International, Inc (NASDAQ:DYAI) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securi
Bank of Montreal Can Purchases 5,279 Shares of Dyadic International, Inc (NASDAQ:DYAI)
05:40am, Friday, 18'th Sep 2020
Bank of Montreal Can lifted its position in Dyadic International, Inc (NASDAQ:DYAI) by 6.1% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission
Global Market Overview of the Industrial Enzymes Market 2020 - ResearchAndMarkets.com
12:00am, Monday, 14'th Sep 2020
The
